Delving into the Latest Updates on NEAT ID Foundation with Synapse

概览

关联

11

项与 NEAT ID Foundation 相关的临床试验

NCT05965427 / RecruitingN/AIIT

Morbidity, Mortality And Risk Factors of Mpox in HIV Negative High Risk Sexual Health Clinic Attenders and People Living With HIV

This data collection study aims to describe and compare the outcomes of Mpox on people living with HIV (PLHIV) and HIV-negative individuals who are on pre-exposure prophylaxis (PrEP). The study also aims to identify risk factors for specific Mpox outcomes.

开始日期2023-12-01

申办/合作机构

NEAT ID Foundation

[+1]

NCT05593770 / Terminated临床2/3期IIT

International Sites: CONNECTS Master Protocol for Clinical Trials Targeting Macro-, Micro-immuno-thrombosis, Vascular Hyperinflammation, and Hypercoagulability and Renin-angiotensin-aldosterone System (RAAS) in Hospitalized Patients With COVID-19 (ACTIV-4 Host Tissue)

The overarching goal of the Master Protocol is to find effective strategies for inpatient management of patients with COVID-19. Therapeutic goals for patients hospitalized for COVID-19 include hastening recovery and preventing progression to critical illness, multiorgan failure, or death. Our objective is to determine whether modulating the host tissue response improves clinical outcomes among patients with COVID-19.

开始日期2022-10-27

申办/合作机构

NEAT ID Foundation

NCT05421806 / CompletedN/AIIT

A Cohort Study of Use of Doravirine (DOR) Based Regimens in Clinical Practice in Europe

Following the initiation of Doravirine (DOR) regimen among people living with HIV (PLWH), the study will aim to assess effectiveness, discontinuation, and resistance over the 12-month period.
Retrospective data from 400 patients, 100 treatment naïve and 300 virally suppressed patients switching from a 1st or second line treatment, is planned to be collected from 6 - 10 European sites.
The study will be conducted through collaboration with the NEAT ID Network, a well-established network of clinical sites across Europe.

开始日期2022-10-10

申办/合作机构

NEAT ID Foundation

[+1]

100 项与 NEAT ID Foundation 相关的临床结果

登录后查看更多信息

0 项与 NEAT ID Foundation 相关的专利（医药）

登录后查看更多信息

1

项与 NEAT ID Foundation 相关的文献（医药）

2021-12-06·Clinical Infectious Diseases

Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care

Article

作者: Zhong, Lijie ; Edgar, Holly ; Bekele, B Nebiyou ; Slim, Jihad ; De Wit, Stéphane ; Wang, Su ; Hu, Hao ; Balani, Bindu ; Diaz-Cuervo, Helena ; Perez, Katherine K ; Osinusi, Anu O ; Olender, Susan A ; Robinson, Philip ; Go, Alan S ; Bernardino, Jose I ; Haubrich, Richard H ; Phulpin, Chloé ; Chokkalingam, Anand P ; Chin, BumSik ; Shah, Nirav S ; Tsang, Tak Yin Owen ; Price-Haywood, Eboni G ; Walunas, Theresa L ; Gottlieb, Robert L ; Lin, Lanjia ; Ali, Shamim M ; Gallant, Joel ; Smith, Lindsey E ; Swaminathan, Shobha ; Brainard, Diana M ; Lee, I-Heng ; Mera-Giler, Robertino ; Soriano Viladomiu, Alex

AbstractBackgroundWe compared the efficacy of the antiviral agent, remdesivir, versus standard-of-care treatment in adults with severe coronavirus disease 2019 (COVID-19) using data from a phase 3 remdesivir trial and a retrospective cohort of patients with severe COVID-19 treated with standard of care.MethodsGS-US-540–5773 is an ongoing phase 3, randomized, open-label trial comparing two courses of remdesivir (remdesivir-cohort). GS-US-540–5807 is an ongoing real-world, retrospective cohort study of clinical outcomes in patients receiving standard-of-care treatment (non-remdesivir-cohort). Inclusion criteria were similar between studies: patients had confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, were hospitalized, had oxygen saturation ≤94% on room air or required supplemental oxygen, and had pulmonary infiltrates. Stabilized inverse probability of treatment weighted multivariable logistic regression was used to estimate the treatment effect of remdesivir versus standard of care. The primary endpoint was the proportion of patients with recovery on day 14, dichotomized from a 7-point clinical status ordinal scale. A key secondary endpoint was mortality.ResultsAfter the inverse probability of treatment weighting procedure, 312 and 818 patients were counted in the remdesivir- and non-remdesivir-cohorts, respectively. At day 14, 74.4% of patients in the remdesivir-cohort had recovered versus 59.0% in the non-remdesivir-cohort (adjusted odds ratio [aOR] 2.03: 95% confidence interval [CI]: 1.34–3.08, P < .001). At day 14, 7.6% of patients in the remdesivir-cohort had died versus 12.5% in the non-remdesivir-cohort (aOR 0.38, 95% CI: .22–.68, P = .001).ConclusionsIn this comparative analysis, by day 14, remdesivir was associated with significantly greater recovery and 62% reduced odds of death versus standard-of-care treatment in patients with severe COVID-19.Clinical Trials RegistrationNCT04292899 and EUPAS34303.

100 项与 NEAT ID Foundation 相关的药物交易

登录后查看更多信息

100 项与 NEAT ID Foundation 相关的转化医学

登录后查看更多信息